HenKan Pharmaceutical

HenKan Pharmaceutical was a specialty pharmaceutical company focused on acquiring and developing innovative pharmaceutical products for clinical and commercial development in Asia, particularly Taiwan, China, and South Korea. Its most notable activity was the exclusive licensing of CRx‑026—a novel dual-action anti-cancer agent targeting mitotic kinesin hsEg5/KSP and PRL phosphatases—from CombinatoRx. As of 2005, CRx‑026 was in phase I/II trials for solid tumors. The company also engaged in sourcing Asian products with proven efficacy for Western markets. Funding came from CDIB BioScience Venture Fund I, Taiwan’s largest life science venture fund at the time.[1][2]